Fisher Asset Management LLC grew its stake in shares of Affimed (NASDAQ:AFMD – Get Rating) by 122.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 895,217 shares of the biopharmaceutical company’s stock after purchasing an additional 493,531 shares during the quarter. Fisher Asset Management LLC owned approximately 0.73% of Affimed worth $1,110,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Knights of Columbus Asset Advisors LLC grew its holdings in Affimed by 60.3% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 238,699 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 89,789 shares in the last quarter. Altium Capital Management LP bought a new position in Affimed in the 3rd quarter worth approximately $1,854,000. Caxton Associates LP grew its holdings in Affimed by 449.6% in the 3rd quarter. Caxton Associates LP now owns 80,824 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 66,119 shares in the last quarter. Intellectus Partners LLC grew its holdings in Affimed by 36.6% in the 4th quarter. Intellectus Partners LLC now owns 366,145 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 98,029 shares in the last quarter. Finally, LMR Partners LLP grew its holdings in Affimed by 4.8% in the 3rd quarter. LMR Partners LLP now owns 541,996 shares of the biopharmaceutical company’s stock worth $1,117,000 after buying an additional 25,000 shares in the last quarter. 61.73% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on AFMD shares. Stifel Nicolaus decreased their price objective on Affimed from $2.00 to $1.00 and set a “hold” rating for the company in a report on Friday, March 24th. Wells Fargo & Company reissued an “overweight” rating and issued a $7.00 price objective on shares of Affimed in a report on Monday, March 27th. StockNews.com downgraded Affimed from a “hold” rating to a “sell” rating in a research report on Friday, March 24th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Affimed in a research report on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.67.
Affimed Stock Performance
About Affimed
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
Read More
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- ExxonMobil Gushes To New Highs
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.
